Literature DB >> 22699199

Early detection of low enhanced pancreatic parenchyma by contrast-enhanced computed tomography predicts poor prognosis of patients with acute pancreatitis.

Morihisa Hirota1, Kennichi Satoh, Kazuhiro Kikuta, Atsushi Masamune, Kiyoshi Kume, Shin Hamada, Akihiko Satoh, Atsushi Kanno, Jun Unno, Hiromichi Ito, Hiroyuki Ariga, Tooru Shimosegawa.   

Abstract

OBJECTIVES: The usefulness of early severity assessment of acute pancreatitis (AP) by contrast-enhanced computed tomography (CECT) was investigated.
METHODS: Data were obtained from a 2007 nationwide survey in Japan. Clinical data of 983 patients with AP were analyzed. All were examined by CECT on the day of admission.
RESULTS: Early findings of CECT demonstrated that low enhanced pancreatic parenchyma (LEPP) was associated with the incidence of organ failure (OF), multiple OF, and infectious complications as well as mortality (P < 0.0001). Next, patients were further divided into 4 groups according to the CECT findings, which focused on the LEPP and peripancreatic collections (PPCs). The LEPP/PPC (+/+) group was characterized as high morbidity and high mortality. The incidence of OF (28.2%), multiple OF (15.5%), and mortality (11.4%) in patients assigned to the (+/+) group was significantly higher than in those assigned to the other groups. The incidence of infectious complications was significantly higher in patients assigned to the (+/+) group (16.7%), the (+/-) group (9.0%), and the (-/+) group (7.0%) than those assigned to the (-/-) group (1.8%).
CONCLUSIONS: The detection of LEPP and PPC was a useful CECT finding for the early assessment of the severity of AP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699199     DOI: 10.1097/MPA.0b013e318249a904

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  2 in total

1.  Validation of the efficacy of the prognostic factor score in the Japanese severity criteria for severe acute pancreatitis: A large multicenter study.

Authors:  Tsukasa Ikeura; Masayasu Horibe; Masamitsu Sanui; Mitsuhito Sasaki; Yasuyuki Kuwagata; Kenichiro Nishi; Shuji Kariya; Hirotaka Sawano; Takashi Goto; Tsuyoshi Hamada; Takuya Oda; Hideto Yasuda; Yuki Ogura; Dai Miyazaki; Kaoru Hirose; Katsuya Kitamura; Nobutaka Chiba; Tetsu Ozaki; Takahiro Yamashita; Toshitaka Koinuma; Taku Oshima; Tomonori Yamamoto; Morihisa Hirota; Satoshi Yamamoto; Kyoji Oe; Tetsuya Ito; Eisuke Iwasaki; Takanori Kanai; Kazuichi Okazaki; Toshihiko Mayumi
Journal:  United European Gastroenterol J       Date:  2016-09-27       Impact factor: 4.623

2.  Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.

Authors:  Morihisa Hirota; Tooru Shimosegawa; Katsuya Kitamura; Kazunori Takeda; Yoshifumi Takeyama; Toshihiko Mayumi; Tetsuhide Ito; Mamoru Takenaka; Eisuke Iwasaki; Hirotaka Sawano; Etsuji Ishida; Shin Miura; Atsushi Masamune; Yousuke Nakai; Akira Mitoro; Hiroyuki Maguchi; Kenji Kimura; Tsuyoshi Sanuki; Tetsuya Ito; Hiroki Haradome; Kazuto Kozaka; Toshifumi Gabata; Keisho Kataoka; Masahiko Hirota; Shuji Isaji; Ryoji Nakamura; Koki Yamagiwa; Chie Kayaba; Koji Ikeda
Journal:  J Gastroenterol       Date:  2019-11-22       Impact factor: 7.527

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.